Who
Stephen C. Glover
Director
Company insider
Files Form 4 as: Director, Oncolytics Biotech; Director, PDS Biotechnology; Chief Executive Officer, ZyVersa Therapeutics; Director, Ambrx Biopharma; Director, Ambrx Biopharma; President Follow-on Biologics, Insmed; Director, Auriga Laboratories.
In numbers
- Trades disclosed
- 53
- Buys
- 3
- Sells
- 0
- Bought
- $138K
- Sold
- $0
- Companies
- 7
- Companies where not an officer
- 5
- First trade
- 10 Dec 2006
- Last trade
- 1 Jun 2026
- Last filed
- 3 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jun 2026filed 3 Jun 2026 | ONCY Oncolytics Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —96,000 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ONCY Oncolytics Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —96,000 at $0.00 | filing |
| 12 Jan 2026filed 3 Mar 2026 | PDSB PDS Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,876 at $0.00 | filing |
| 12 Jan 2026filed 3 Mar 2026 | PDSB PDS Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,876 at $0.00 | filing |
| 11 Jul 2025filed 15 Jul 2025 | ZyVersa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —136,900 at $0.00 | filing |
| 11 Jun 2025filed 11 Jun 2025 | PDSB PDS Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,700 at $0.00 | filing |
| 28 Feb 2025filed 3 Mar 2025 | PDSB PDS Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code P | —15,061 | filing |
| 28 Feb 2025filed 3 Mar 2025 | PDSB PDS BiotechnologyBiotechnology | SEC FORM 4 Bought | $25K15,061 at $1.66 | filing |
| 24 Jun 2024filed 25 Jun 2024 | PDSB PDS Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 7 Mar 2024filed 7 Mar 2024 | Ambrx Biopharmaoption or derivative | SEC FORM 4 Code D | —12,142 | filing |
| 7 Mar 2024filed 7 Mar 2024 | Ambrx Biopharmaoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 7 Mar 2024filed 7 Mar 2024 | Ambrx Biopharmaoption or derivative | SEC FORM 4 Code D | —2,500 | filing |
| 7 Mar 2024filed 7 Mar 2024 | Ambrx Biopharmaoption or derivative | SEC FORM 4 Code D | —5,714 | filing |
| 14 Jul 2023filed 17 Jul 2023 | PDSB PDS Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 7 Jun 2023filed 9 Jun 2023 | Ambrx Biopharmaoption or derivative | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 7 Jun 2023filed 9 Jun 2023 | Ambrx Biopharma | SEC FORM 4 Code A | —85,000 at $0.00 | filing |
| 24 May 2023filed 18 Jul 2024 | ZyVersa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,627 at $0.00 | filing |
| 18 May 2023filed 9 Jun 2023 | Ambrx Biopharmaoption or derivative | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 18 May 2023filed 26 May 2023 | Ambrx Biopharmaoption or derivative | SEC FORM 4 Code A | —210,000 at $0.00 | filing |
| 12 Dec 2022filed 14 Dec 2022 | ZyVersa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18 | filing |
News
PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of DirectorsPDSB · manilatimes.net · 20 Oct 2026
0 headlines in the last 90 days name Stephen C. Glover; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.